There Might Be a Better Time to Pop That Pill
Syncing cures with circadian rhythms is an idea whose moment has finally come.
Take These Drugs to Get to Mars
Space brain and other cosmic problems demand new kinds of pharmaceutical protection.
How a DNA Test Can Help You Deal with Depression
Gene tests for antidepressants are going mainstream — and getting more confusing. Here’s a guide.
Your Next Rx: Less Testing, Fewer Drugs — and Better Health
Soon, precision medicine could help you avoid expensive, risky procedures that you may not need.
The Latest Biotech Growth Market Might be Crap
There’s gold in your gut—and startups are mining it with microbiome science. The biggest hurdle? Stool doesn’t scale.
This Scientist-Turned-VC Wants to Extend Life
Since he was a child, James Peyer has been obsessed with stopping aging. Now he has a fund — and a plan.
Medicine Ignored This Insulin Problem. Hackers Solved It.
“I’m just a girl living with type 1 diabetes who got tired of waiting.”
Get In On the Sale of Yourself
After watching medical records get traded for billions of dollars, a tech entrepreneur says he can help you grab a share of the bounty.
Check Out This Beating Mini-Heart in a Jar
It’s made out of living human cells. Someday they could be yours.
The Clock is Ticking Faster for a Patient Turned Medical Disruptor
Investors and families are counting on Onno Faber to galvanize research into neglected conditions—like the one threatening his hearing and sight.
Shake Up the Snow Globe in Your Mind
Michael Pollan explores the neuroscience of psychedelics in this excerpt from his new book.
Longevity, the Greatest Investment Opportunity of All Time
Billionaire Jim Mellon bets that a “stock market mania” will be sparked by technologies that make people live past 100.
You Can Rescue Medical Breakthroughs from the Valley of Death
Halo Cures, a crowdfunding startup, will usher new drugs and devices through the rockiest stage of development.
More on the Supposed Youth Pill
A new study helps the case for a supplement known as NR, but it’s not yet a slam dunk.